pharma
Secura Bio
Secura Bio Limited
Secura Bio is a pharma organization headquartered in GB. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. P
Company details
- Status
- Public
- HQ
- Berkeley Heights, USA
- Founded
- 2019
- Employees
- 55
- Programs
- 1
- Drugs
- 7
- Patents
- 0
SBI-0145-304
Phase 3 · small molecule · relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype
SBI-0145-304 for relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype is a Phase 3 program (small_molecule) at Secura Bio Limited with 1 ClinicalTrials.gov record(s).
Internal code SBI-0145-304
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Secura Bio Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype
- Status
- active
- Trials
- 1